ADMA Biologics, Inc.
ADMA
$16.16
-$0.42-2.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.63% | 27.62% | 43.58% | 62.22% | 65.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.63% | 27.62% | 43.58% | 62.22% | 65.15% |
| Cost of Revenue | 5.08% | 14.41% | 26.74% | 28.49% | 23.76% |
| Gross Profit | 33.35% | 41.12% | 62.77% | 112.56% | 141.16% |
| SG&A Expenses | 23.03% | 39.08% | 43.14% | 38.37% | 25.22% |
| Depreciation & Amortization | -62.37% | -78.18% | -84.31% | -70.19% | -46.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.87% | 21.28% | 30.81% | 30.17% | 22.96% |
| Operating Income | 37.74% | 41.91% | 79.43% | 223.04% | 468.86% |
| Income Before Tax | 45.30% | 112.35% | 270.19% | 4,715.18% | 545.16% |
| Income Tax Expenses | 149.65% | -1,127.41% | -1,558.01% | -11,193.78% | -- |
| Earnings from Continuing Operations | -25.67% | 207.41% | 500.57% | 5,772.73% | 799.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.67% | 207.41% | 500.57% | 5,772.73% | 799.98% |
| EBIT | 37.74% | 41.91% | 79.43% | 223.04% | 468.86% |
| EBITDA | 35.71% | 39.00% | 71.97% | 188.29% | 348.75% |
| EPS Basic | -26.97% | 202.99% | 491.41% | 5,113.71% | 768.86% |
| Normalized Basic EPS | 43.36% | 52.25% | 109.51% | 433.52% | 24,150.00% |
| EPS Diluted | -23.24% | 195.87% | 495.16% | 3,867.13% | 701.15% |
| Normalized Diluted EPS | 45.23% | 53.04% | 108.76% | 427.00% | 27,091.67% |
| Average Basic Shares Outstanding | 2.53% | 3.52% | 4.14% | 4.25% | 4.07% |
| Average Diluted Shares Outstanding | 1.29% | 3.63% | 4.87% | 6.39% | 7.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |